Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 56 of 6351
-
Can a vitamin boost Babies' brains before birth?
Prevention Recruiting nowThiamine (vitamin B1) is an important nutrient needed for energy metabolism, brain development, and overall health. However, low thiamine intake is a concern in countries where white rice is the main staple since it contains little thiamine. If pregnant or breastfeeding women do …
Sponsor: Mount Saint Vincent University • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
Gene therapy aims to fix bone marrow failure in fanconi anemia
Disease control Stopped earlyThis is a Phase I/II clinical trial of gene therapy for treating Fanconi anemia using a self-inactivating lentiviral vector to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New lung cancer cocktail aims to outperform current standard therapy
Disease control Not yet recruitingEfficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
Phase 2/3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Spinal cord zap may help people breathe again after neck injury
Disease control Recruiting nowThis multicenter, single-arm exploratory IIT evaluates epidural spinal cord electrical stimulation (ESCES) in 20 adults with C1-C5 SCI and respiratory failure. Participants receive ESCES plus standard care; electrodes are implanted at C3-C5 with daily individualized stimulation. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to fight resistant lung cancer
Disease control Not yet recruitingThis study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC. The Phase III study is planned to enroll approximately 680 participants, who will be randomized in a 1:1 ratio into the followin…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood test could spare stomach cancer patients from unnecessary chemo
Disease control Not yet recruitingFor locally advanced gastric adenocarcinoma/esophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including chemotherapy, immunotherapy, etc.). This approach involv…
Phase 3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough lung cancer: experimental drug takes on KRAS mutation
Disease control Not yet recruitingThe study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Liver transplant may beat surgery for certain colorectal cancer patients
Disease control Recruiting nowThe TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and/or ablation) in patients with initially unresectable colorectal liver metastases (CRLM) converted to resectabilit…
Sponsor: Niguarda Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for stroke patients: drug may restore brain function hours later
Disease control Not yet recruitingThis study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokin…
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug could help boys with duchenne walk and move longer
Disease control Recruiting nowThe purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable t…
Phase 3 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to keep lung cancer at bay
Disease control Not yet recruitingThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in patients with unresectable EGFR-mutated Stage III non-small cell lung cancer who have not progressed following pl…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New model aims to cure hepatitis c in homeless drug users
Cure Recruiting nowThe objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) …
Sponsor: University of Washington • Aim: Cure
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Stopped earlyThe purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and funct…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
Disease control Stopped earlyThe purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cervical cancer
Disease control Stopped earlyThe primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on COVID-19: a novel vaccine approach
Vaccine Stopped earlyIn December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat a…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Vaccine
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy targets tough leukemia in adults
Disease control Recruiting nowThis open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to stop liver cancer spread in its tracks
Disease control Not yet recruitingThis study evaluates whether comprehensive local consolidative therapy added to continued sintilimab plus lenvatinib improves survival compared with continued sintilimab plus lenvatinib alone in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. All enrolled pa…
Phase 3 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a Triple-Drug combo erase rectal tumors before surgery?
Disease control Recruiting nowObservation and evaluation of the safety and efficacy of PD-1 antibody combined with IBI310 and neoadjuvant chemotherapy in the treatment of locally advanced rectal cancer Primary objectives: Pathological complete response (pCR) rate; Secondary objectives: Treatment-related a…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New shot could cut heart attacks and strokes in High-Risk patients
Disease control Recruiting nowThe purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Phase 3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC